Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tissue pharmacokinetics of daptomycin in diabetic foot infection
2008-006949-75Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Jun 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daptomycin in diabetic foot infection (DFI), skin and soft tissue infections (SSTIs) and type 2 diabetes mellitus (T2DM), sponsored by Medical University of Graz. Primary endpoint: Pharmacokinetic profile of daptomycin in inflamed subcutaneous adipose tissue. Started Jun 2009; status: completed.
02
Drugs
daptomycin
03
Conditions
diabetic foot infection (DFI)skin and soft tissue infections (SSTIs)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006949-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006949-75.